SCHEMBL856447

SCHEMBL856447

CS(=O)(=O)OCc1c(F)cc(Br)cc1F

nearest known ligand 0.34

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
APLNR P35414 2/20 0.32
KDM4E B2RXH2 1/20 0.31
USP2 O75604 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
MMP9 P14780 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
DGAT1 O75907 1/20 0.31
AKR1B1 P15121 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31310164 0.87 HTR6 (0.33) APLNRALDH1A1LMNAALOX15TSHR
SCHEMBL26933279 0.81 CA12 (0.32) APLNR
SCHEMBL14709472 0.79 HTR1D (0.33) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL3713112 0.77 LMNA (0.40) KDM4EALDH1A1LMNA
SCHEMBL2800941 0.77 EPAS1 (0.36)
SCHEMBL4816671 0.77 AKR1B1 (0.42) APLNRAKR1B1
SCHEMBL17197208 0.76 NR1I2 (0.33)
SCHEMBL378265 0.76 PTGS2 (0.38) ALDH1A1LMNA
SCHEMBL15164140 0.76 KCNQ2 (0.35) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL3942239 0.75 IDO1 (0.37) MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10077241-B2 Tetrahydro-benzoimidazolyl modulators of TGR5 JANSEN PHARMACEUTICA NV (BE) 2018-09-18 US disclosed
US-20170029381-A1 TETRAHYDRO-BENZOIMIDAZOLYL MODULATORS OF TGR5 JANSSEN PHARMACEUTICA NV (BE) 2017-02-02 US disclosed
US-9540371-B2 Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1 VANDERBILT UNIVERSITY (US) 2017-01-10 US disclosed
US-9527834-B2 Substituted 1-benzylquinoxalin-2(1H)-one analogs as positive allosteric modulators of muscarinic acetylcholine receptor M1 VANDERBILT UNIVERSITY (US) 2016-12-27 US disclosed
US-9527834-B2 Substituted 1-benzylquinoxalin-2(1H)-one analogs as positive allosteric modulators of muscarinic acetylcholine receptor M1 VANDERBILT UNIVERSITY (US) 2016-12-27 US disclosed
US-20160102090-A1 SUBSTITUTED 3-BENZYLQUINOXALIN-4(3H)-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYCHOLINE RECEPTOR M1 VANDERBILT UNIVERSITY (US) 2016-04-14 US disclosed
US-20160075690-A1 SUBSTITUTED 1-BENZYLQUINOXALIN-2(1H) ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-03-17 US disclosed
WO-2014179237-A1 SUBSTITUTED 3-BENZYLQUINOXALIN-4(3H)-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYCHOLINE RECEPTOR M1 VANDERBILT UNIVERSITY (US) 2014-11-06 WO disclosed
WO-2014179226-A1 SUBSTITUTED 1-BENZYLQUINOXALIN-2 (1H)-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 VANDERBILT UNIVERSITY (US) 2014-11-06 WO disclosed
US-8563714-B2 Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists ACTELION PHARMACEUTICALS LTD. (CH) 2013-10-22 US disclosed
US-20090131472-A1 P38 Kinase Inhibiting Agents MERCK SHARP & DOHME LLC 2009-05-21 US disclosed
US-20090131472-A1 P38 Kinase Inhibiting Agents MERCK SHARP & DOHME LLC 2009-05-21 US disclosed
US-20090131472-A1 P38 Kinase Inhibiting Agents MERCK SHARP & DOHME LLC 2009-05-21 US disclosed
US-20080318962-A1 Fungicides Based on Nitrogen-Containing Heterocycles SYNGENTA CROP PROTECTION, INC. (US) 2008-12-25 US disclosed
CN-101273039-A Heterobicyclic compounds useful as p38 kinase inhibitors MERCK & CO INC (US) 2008-09-24 CN disclosed
EP-1915373-A1 HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS Merck and Co., Inc. (US) 2008-04-30 EP disclosed
EP-1771423-A1 FUNGICIDES BASED ON NITROGEN-CONTAINING HETEROCYCLES Syngeta Participations AG (CH) 2007-04-11 EP disclosed
WO-2007021710-A1 HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS MERCK & CO., INC. (US) 2007-02-22 WO disclosed
WO-2007021710-A1 HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS MERCK & CO., INC. (US) 2007-02-22 WO disclosed
WO-2005123698-A1 FUNGICIDES BASED ON NITROGEN-CONTAINING HETEROCYCLES SYNGENTA PARTICIPATIONS AG (CH) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160075690-A1 SUBSTITUTED 1-BENZYLQUINOXALIN-2(1H) ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 CHRM1, CHRM2, CHRM5 APLNR 835/4885KDM4E 997/4885USP2 2248/4885
US-20090131472-A1 P38 Kinase Inhibiting Agents MAPK1, MAPK8, MAPK7 APLNR 4128/4885KDM4E 4346/4885USP2 3320/4885
US-10077241-B2 Tetrahydro-benzoimidazolyl modulators of TGR5 GLRA1, GRM5, TRHR APLNR 504/4885KDM4E 950/4885USP2 3374/4885
US-20170029381-A1 TETRAHYDRO-BENZOIMIDAZOLYL MODULATORS OF TGR5 GLRA1, GRM5, TRHR APLNR 504/4885KDM4E 950/4885USP2 3374/4885
US-20080318962-A1 Fungicides Based on Nitrogen-Containing Heterocycles DDT, CYP4X1, CBR1 APLNR 3673/4885KDM4E 471/4885USP2 2582/4885
US-20160102090-A1 SUBSTITUTED 3-BENZYLQUINOXALIN-4(3H)-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYCHOLINE RECEPTOR M1 CHRM1, CHRM3, CHRM4 APLNR 591/4885KDM4E 882/4885USP2 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.